7AL Stock Overview
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.083 |
| 52 Week High | kr0.12 |
| 52 Week Low | kr0.021 |
| Beta | 1.34 |
| 1 Month Change | 4.13% |
| 3 Month Change | -9.55% |
| 1 Year Change | -7.44% |
| 3 Year Change | -84.72% |
| 5 Year Change | -96.46% |
| Change since IPO | -97.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7AL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.1% | -4.3% | -2.5% |
| 1Y | -7.4% | -19.4% | -0.4% |
Return vs Industry: 7AL exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 7AL underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 7AL volatility | |
|---|---|
| 7AL Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7AL's share price has been volatile over the past 3 months.
Volatility Over Time: 7AL's weekly volatility has decreased from 33% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 58 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| 7AL fundamental statistics | |
|---|---|
| Market cap | €67.54m |
| Earnings (TTM) | -€21.30m |
| Revenue (TTM) | €5.08m |
13.3x
P/S Ratio-3.2x
P/E RatioIs 7AL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7AL income statement (TTM) | |
|---|---|
| Revenue | kr59.25m |
| Cost of Revenue | kr218.79m |
| Gross Profit | -kr159.54m |
| Other Expenses | kr89.05m |
| Earnings | -kr248.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -269.26% |
| Net Profit Margin | -419.55% |
| Debt/Equity Ratio | 0% |
How did 7AL perform over the long term?
See historical performance and comparison